Resistance to targeted therapies: delving into FLT3 and IDH

Recent advances in FLT3 and IDH targeted inhibition have improved response rates and overall survival in patients with mutations affecting these respective proteins. Despite this success, resistance mechanisms have arisen including mutations that disrupt inhibitor-target interaction, mutations impac...

Descripción completa

Detalles Bibliográficos
Autores principales: Desikan, Sai Prasad, Daver, Naval, DiNardo, Courtney, Kadia, Tapan, Konopleva, Marina, Ravandi, Farhad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9184476/
https://www.ncbi.nlm.nih.gov/pubmed/35680852
http://dx.doi.org/10.1038/s41408-022-00687-5
Descripción
Sumario:Recent advances in FLT3 and IDH targeted inhibition have improved response rates and overall survival in patients with mutations affecting these respective proteins. Despite this success, resistance mechanisms have arisen including mutations that disrupt inhibitor-target interaction, mutations impacting alternate pathways, and changes in the microenvironment. Here we review the role of these proteins in leukemogenesis, their respective inhibitors, mechanisms of resistance, and briefly ongoing studies aimed at overcoming resistance.

Ejemplares similares